The global Wilson’s Disease Treatment Market is estimated to be valued at US$ 560.2 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Wilson's disease is a rare inherited disorder in which copper builds up in the body. It primarily affects the liver and brain. The disease develops due to faulty copper transport, leading to excess copper accumulation. Common treatments for Wilson's disease include chelating agents, which bind and remove excess copper from the body.
Market key trends:
Market key trends:
One of the key trends in the Wilson's disease treatment market is the rising adoption of artificial intelligence in disease diagnosis and management. AI tools are being used to analyze various diagnostic parameters such as medical history, symptoms, laboratory test results etc. to accurately diagnose Wilson's disease at an early stage. This is significantly improving disease management and outcomes. AI aids in developing personalized treatment plans, predicting disease progression, and monitoring treatment response in patients.
Segment Analysis
The global Wilson's disease treatment market can be segmented based on treatment type and region. Based on treatment type, the market is segmented into copper removal therapies and supportive therapies. Copper removal therapies hold the dominant market share owing to their effectiveness in treating Wilson's disease. Medications such as D-penicillamine and trientine are used for copper removal and account for over 60% of the total market.
Key Takeaways
Market size
The global Wilson's disease treatment market is expected to witness high growth, exhibiting a CAGR of 6.3% over the forecast period, due to increasing prevalence of Wilson's disease. As per estimates, around 1 in 30,000 people worldwide suffer from Wilson's disease.
Regional analysis
North America holds the dominant share in the global Wilson's disease treatment market owing to the high treatment rate and increasing healthcare expenditure. Europe is the second largest market for Wilson's disease treatment. However, Asia Pacific is expected to witness the highest growth rate over the forecast period owing to improving healthcare infrastructure and increasing awareness about Wilson's disease.
Key players
Key players operating in the Wilson’s disease treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co. Merck & Co. and Teva Pharmaceuticals USA, Inc. hold the major market share as they offer effective generic medications for Wilson's disease.
Segment Analysis
The global Wilson's disease treatment market can be segmented based on treatment type and region. Based on treatment type, the market is segmented into copper removal therapies and supportive therapies. Copper removal therapies hold the dominant market share owing to their effectiveness in treating Wilson's disease. Medications such as D-penicillamine and trientine are used for copper removal and account for over 60% of the total market.
Key Takeaways
Market size
The global Wilson's disease treatment market is expected to witness high growth, exhibiting a CAGR of 6.3% over the forecast period, due to increasing prevalence of Wilson's disease. As per estimates, around 1 in 30,000 people worldwide suffer from Wilson's disease.
Regional analysis
North America holds the dominant share in the global Wilson's disease treatment market owing to the high treatment rate and increasing healthcare expenditure. Europe is the second largest market for Wilson's disease treatment. However, Asia Pacific is expected to witness the highest growth rate over the forecast period owing to improving healthcare infrastructure and increasing awareness about Wilson's disease.
Key players
Key players operating in the Wilson’s disease treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura & Co. Merck & Co. and Teva Pharmaceuticals USA, Inc. hold the major market share as they offer effective generic medications for Wilson's disease.
No comments:
Post a Comment